The fact folks think a stock with billions in os can move up from here is insane. Like all bio stocks they’ll r/s and issue more convertible notes. They have nothing but debt and years before an approved product. If they even want to contemplate the Nasdaq they’ll still have to rs. Investors won’t win here.
Market Data 
Markets
AI
